Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity & Safety of GSK's Thimerosal-free TIV in Children
NCT00980005Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fluzone Trivalent in influenza (2 arms), sponsored by GSK. Primary endpoints: Geometric Mean of Haemagglutination Inhibiting (HI) Antibodies Titers Against the Three Strains at Day 28 and Number of Seroconverted Subjects for HI Antibodies Against the Three Strains at Day 28. Started Oct 2009; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00980005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00980005.